Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed.

1. Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy.Biomolecules · 2024
   Article
2. Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy.Nature communications · 2024
   Article
3. Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer.Journal for immunotherapy of cancer · 2023
   Review
4. Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.Journal for immunotherapy of cancer · 2023
   Article
5. Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.The oncologist · 2022
   Article
6. Advanced non-small-cell lung cancer: how to manage non-oncogene disease.Drugs in context · 2022
   Review
7. TGFβ2 is a Prognostic Biomarker for Gastric Cancer and is Associated With Methylation and Immunotherapy Responses.Frontiers in genetics · 2022
   Article
8. Pan-cancer landscape ofJournal for immunotherapy of cancer · 2021
   Article
9. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.Cancer medicine · 2021
   Article
10. Frontiers in immunology · 2021
    Article
11. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.Cancers · 2020
    Review
12. Integrating Systems Biology and an Ex Vivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics.iScience · 2020
    Article
13. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.Journal of translational medicine · 2020
    Article
14. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?Frontiers in immunology · 2020
    Review
15. Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.Therapeutic advances in medical oncology · 2020
    Article
16. RANBP9 as potential therapeutic target in non-small cell lung cancer.Journal of cancer metastasis and treatment · 2020
    Article
17. Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.Clinical pharmacology and therapeutics · 2019
    Review
18. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.Nature reviews. Clinical oncology · 2019
    Review
19. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.Nature reviews. Cancer · 2019
    Review
20. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.Nature medicine · 2018
    Article

Corrections and comments

• Comment on
  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.2017

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as